Clinical Trials Provider Soars, Clears Buy Point On Solid Q2 Results

Shares of Iqvia (IQV) surged past a buy point Tuesday after the provider of clinical research services beat second-quarter estimates and raised guidance. Revenue climbed 8.7% to $4.368 billion year over year, while adjusted earnings increased 12% to $3.15 a share. Analysts, on average, expected revenue of $4.310 billion. The consensus earnings estimate was $3.03 per share, with the highest…